Symlin (pramlintide) / AstraZeneca |
NCT00240253: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes |
|
|
| Completed | 4 | 200 | US | pramlintide acetate | AstraZeneca | Type 2 Diabetes Mellitus | 06/06 | 06/06 | | |
NCT00291772: Continuous Subcutaneous Infusion of Pramlintide and Insulin |
|
|
| Completed | 4 | 13 | US | Pramlintide, Symlin | Baylor College of Medicine | Type 1 Diabetes | 11/07 | 11/07 | | |
NCT00502138: A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes |
|
|
| Completed | 4 | 12 | US | Continuous Pramlintide infusion, pramlintide | University Diabetes & Endocrine Consultants, Amylin Pharmaceuticals, LLC. | IDDM | 01/08 | 01/08 | | |
NCT00467649: A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes |
|
|
| Completed | 4 | 112 | US | pramlintide acetate (Symlin), Symlin, rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir]) | AstraZeneca | Type 2 Diabetes Mellitus | 04/08 | 04/08 | | |
NCT00505882: Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes |
|
|
| Withdrawn | 4 | 0 | US | Pramlintide, Symlin, Glargine, Lispro, Aspart | University of Texas Southwestern Medical Center | Type 1 Diabetes | 12/08 | 12/08 | | |
NCT00442767: Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus |
|
|
| Completed | 4 | 8 | US | Insulin, aspart or lispro, Pramlintide + Insulin, Pramlintide Acetate | Montefiore Medical Center, Amylin Pharmaceuticals, LLC. | Type 1 Diabetes Mellitus | 02/09 | 02/09 | | |
NCT00950677: The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes |
|
|
| Completed | 4 | 16 | US | Byetta (exenatide), Symlin (pramlintide) | Baylor College of Medicine, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes | 05/11 | 05/11 | | |
NCT00690235: Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia |
|
|
| Completed | 4 | 33 | US | Pramlintide, Amylin, Placebo, sterile saline | University of Texas Southwestern Medical Center, Amylin Pharmaceuticals, LLC. | Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain | 08/11 | 08/11 | | |
NCT01269047: Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia |
|
|
| Completed | 4 | 37 | US | Pramlintide, Symlin, Exenatide, Byetta, Type 1 diabetes, Insulin, Novolog, Humalog, Levemir, Lantus | Albert Einstein College of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes | 08/16 | 12/16 | | |